binimetinib

Overview

Binimetinib is a selective MEK1/2 inhibitor approved in combination with encorafenib for BRAF V600E/K-mutant melanoma. It inhibits the RAS/RAF/MEK/ERK signaling cascade.

Evidence in the corpus

• Binimetinib (MEK inhibitor) was among MAPK-pathway directed therapies evaluated across BRAF fusion-positive tumors (N=241, 52 histologies); MEK inhibitor monotherapy provided durable benefit particularly in pilocytic astrocytomas, while combination BRAF+MEK inhibition was less durable (median 1 month) PMID:38922339.
• MEK inhibitor; proposed as therapeutic candidate for KRAS/NRAS/GNAQ-altered cisplatin-resistant GCT alongside trametinib and selumetinib per Appendix Table A2 of the cisplatin-resistance biomarker study (N=180 advanced GCT) PMID:27646943

Resistance mechanisms

• Not directly characterized in the corpus.

Cancer types (linked)

• LUAD

Sources

• PMID:38922339

This page was processed by crosslinker on 2026-05-04. - PMID:27646943

This page was processed by wiki-cli on 2026-05-14.